Your browser doesn't support javascript.
loading
Recurrence of Phaeochromocytoma and Abdominal Paraganglioma After Initial Surgical Intervention.
Johnston, Philip C; Mullan, Karen R; Atkinson, A Brew; Eatock, Fiona C; Wallace, Helen; Gray, Moyra; Hunter, Steven J.
Afiliación
  • Johnston PC; Regional Centre for Endocrinology and Diabetes.
  • Mullan KR; Regional Centre for Endocrinology and Diabetes.
  • Atkinson AB; Regional Centre for Endocrinology and Diabetes.
  • Eatock FC; Department of Endocrine Surgery.
  • Wallace H; Regional Centre for Endocrinology and Diabetes.
  • Gray M; Department of Pathology, Royal Victoria Hospital, Belfast, UK.
  • Hunter SJ; Regional Centre for Endocrinology and Diabetes.
Ulster Med J ; 84(2): 102-6, 2015 May.
Article en En | MEDLINE | ID: mdl-26170485
BACKGROUND: Clinical and biochemical follow up after surgery for phaeochromocytoma is essential with long term studies demonstrating recurrence frequencies between 6% and 23%. AIM: To examine the characteristics and frequency of tumour recurrence in a regional endocrine referral centre, in patients with surgical resection of phaeochromocytoma (P) and abdominal paraganglioma (AP). METHODS: We identified a cohort of 52 consecutive patients who attended our Regional Endocrinology & Diabetes Centre and retrospectively reviewed their clinical, biochemical and radiological data (between 2002 and 2013). After confirmation of early post-operative remission by negative biochemical testing, tumour recurrence was defined by demonstration of catecholamine excess with confirmatory imaging. RESULTS: Phaeochromocytoma was confirmed histologically in all cases (43:P, 9:AP, mean-age:53 years). Open adrenalectomy was performed in 20 cases and laparoscopically in 32. Hereditary phaeochromocytoma was confirmed by genetic analysis in 12 (23%) patients. Median follow up time from initial surgery was 47 months, (range: 12 - 296 months), 49 patients had no evidence of tumour recurrence at latest follow-up. Three patients (6%) demonstrated tumour development, one in a patient with VHL which occurred in a contralateral adrenal gland, one sporadic case had local recurrence, and an adrenal tumour occurred in a patient with a SDHB gene mutation who had a previous bladder tumour. After initial surgery, the tumours occurred at 8.6, 12.0 and 17.7 years respectively. CONCLUSION: In this study tumour development occurred in 6% of patients. Although tumour rates were low, careful and sustained clinical and biochemical follow up is advocated, as new tumour development or recurrence may occur long after the initial surgery is performed.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Feocromocitoma / Neoplasias de las Glándulas Suprarrenales / Paraganglioma Extraadrenal / Neoplasias Abdominales / Recurrencia Local de Neoplasia Tipo de estudio: Prognostic_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Ulster Med J Año: 2015 Tipo del documento: Article Pais de publicación: Irlanda del Norte

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Feocromocitoma / Neoplasias de las Glándulas Suprarrenales / Paraganglioma Extraadrenal / Neoplasias Abdominales / Recurrencia Local de Neoplasia Tipo de estudio: Prognostic_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Ulster Med J Año: 2015 Tipo del documento: Article Pais de publicación: Irlanda del Norte